AMT 126 - Cyclo Therapeutics
Alternative Names: AMT-126 Cyclo TherapeuticsLatest Information Update: 01 Jan 2024
At a glance
- Originator Applied Molecular Transport
- Developer Cyclo Therapeutics
- Class Anti-inflammatories; Recombinant fusion proteins
- Mechanism of Action Interleukin-22 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Gastrointestinal disorders
Most Recent Events
- 27 Dec 2023 Applied Molecular Transport has merged with Cyclo Therapeutics to form Cyclo Therapeutics
- 29 Mar 2023 AMT 126 - Applied Molecular Transport is available for licensing as of 27 Mar 2023. www.appliedmt.com
- 27 Mar 2023 Suspended - Phase-I for Gastrointestinal disorders (In volunteers) in United Kingdom (PO)